Successful desensitization of donor-specific antibodies in a single cord blood transplant recipient
Mégane Tanguay1, Sandra Cohen1, Isabelle Ménard1
1Cellular Therapy & Transplantation Program, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada.
Objective: Umbilical cord blood (UCB) represents a valuable graft source in the absence of a human leukocyte antigen (HLA)-matched donor for hematopoietic cell transplantation (HCT). Donor-specific anti-HLA antibodies (DSAs), targeting grafts with mismatched HLA antigens, pose a significant obstacle by increasing the risk of primary graft failure, delayed engraftment, and decreased survival. Existing literature on HLA desensitization has primarily focused on haploidentical transplants, and there is a lack of experience regarding the optimal strategy in UCB transplantation.Methods: We report our successful desensitization strategy in a 42-year-old woman with acute lymphoblastic leukemia receiving a single UCB unit. The only suitable donor option for this patient, who had no relatives and uncommon HLA haplotypes, was a UCB graft against which the patient had DQ7 DSAs.Results: DSA levels were reduced before transplantation through a combination of plasma exchange, intravenous immunoglobulins, and rituximab with close monitoring of DSA mean fluorescent intensity levels. After desensitization, the patient underwent UCB transplantation, achieved successful engraftment and remained in complete remission, free from graft-versus-host disease.Conclusion: When other suitable donors without DSAs are unavailable, our desensitization modality offers a safe option for single-unit UCB transplantation.
Objective: Umbilical cord blood (UCB) represents a valuable graft source in the absence of a human leukocyte antigen (HLA)-matched donor for hematopoietic cell transplantation (HCT). Donor-specific anti-HLA antibodies (DSAs), targeting grafts with mismatched HLA antigens, pose a significant obstacle by increasing the risk of primary graft failure, delayed engraftment, and decreased survival. Existing literature on HLA desensitization has primarily focused on haploidentical transplants, and there is a lack of experience regarding the optimal strategy in UCB transplantation.Methods: We report our successful desensitization strategy in a 42-year-old woman with acute lymphoblastic leukemia receiving a single UCB unit. The only suitable donor option for this patient, who had no relatives and uncommon HLA haplotypes, was a UCB graft against which the patient had DQ7 DSAs.Results: DSA levels were reduced before transplantation through a combination of plasma exchange, intravenous immunoglobulins, and rituximab with close monitoring of DSA mean fluorescent intensity levels. After desensitization, the patient underwent UCB transplantation, achieved successful engraftment and remained in complete remission, free from graft-versus-host disease.Conclusion: When other suitable donors without DSAs are unavailable, our desensitization modality offers a safe option for single-unit UCB transplantation.
More Related Videos
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Cell-mediated Immune Responses
